Hey there, readers! Take a look at our GPCR coverage for this week. We've got 11 GPCR papers, seven industry news pieces, a new GPCR event, and even a job ad.   This week's highlight includes congrats to: Miles Thompson , Alexander Hauser , Caroline Gorvin ,   et al.   for their work on GPCR gene variants and human genetic disease Ilana Kotliar , Thomas Sakmar , et al. for their study on Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins Nicholas Kapolka , Geoffrey Taghon , and Daniel Isom  for their research on Advances in yeast synthetic biology for human GPCR biology and pharmacology Dr. GPCR University Early-Bird Registration Open for Premium Members! Unlock a 25% exclusive discount on these courses with Dr. Terry Kenakin with our premium membership and enjoy a 1-month FREE trial! Don’t miss out—secure your spot today! Registrations for the public will be on Monday! Hurry! Courses Schedule and  Benefits Every Thursday at 10 am EST Online Lectures 1:1 meeting with Dr. Terry Kenakin Reading Materials Access to the private group Certificate of participation Learn the essentials: Measuring the pharmacologic activity of ligands (affinity, efficacy, co-operativity) Determining mechanisms of action for new GPCR ligands Elements of a comprehensive and effective GPCR discovery Master advanced applications: Using new cellular assays to analyze GPCR ligand behavior Predicting activity and in vivo target coverage with real-time kinetics Discovering new ligands and GPCR behaviors for unique drug profiles   GPCR Event Highlight 11th Adhesion GPCR Workshop Join us in vibrant Mexico City from October 23-25, 2024, to connect with fellow scientists and explore the latest in adhesion GPCR biology. Logo Contest : Let your creativity shine by submitting your design for the Logo Contest before August 15, 2024 Sponsorship Opportunities :   Elevate your brand's presence at this scientific event . Contact us at Hello@DrGPCR.com   to learn more. Your participation is eagerly awaited!  Let’s dive into the   Classified GPCR News  from July 29th to August 4th, 2024 GPCR Activation and Signaling ONE-GO: Direct detection of context-dependent GPCR activity Multiplexed mapping of the interactome of GPCRs with receptor activity-modifying proteins Molecular mechanism of bitter taste receptor agonist-mediated relaxation of airway smooth muscle GPCR Binders, Drugs, and more Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators GPCRs in Oncology and Immunology G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression Methods & Updates in GPCR Research GPCR Signaling: A Study of the Interplay Between Structure, Energy, and Function Engineering a GPCR-based yeast biosensor for a highly sensitive melatonin detection from fermented beverages The calcium-binding photoprotein clytin II: Expression of the preferred human codon-optimized clytin II gene in Chinese hamster ovary-K1 cells and its use in the G-protein-coupled receptor assays Predicting the Hallucinogenic Potential of Molecules Using Artificial Intelligence Reviews, GPCRs, and more G protein-coupled receptor (GPCR) gene variants and human genetic disease Advances in yeast synthetic biology for human G protein-coupled receptor biology and pharmacology Industry News Muscarinic drugs breathe new life into schizophrenia pipeline GPCR Dynamics Reveal Mechanisms for Drug Discovery DMS: Linking Protein Structure To Function AbbVie Completes Acquisition of Cerevel Therapeutics Nxera Pharma attended the Drug Discovery Ecosystem Summit Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45   GPCR Events, Meetings, and Webinars September 18, 2024 | FREE Webinar - The value of GPCR cell-based assays in drug discovery October 2024 | Biologics US 2024   October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry NEW October 17, 2024 | Unprecedented fragment-based screening using Spectral Shift for GPCRs October 23 - 25, 2024 | 11th Adhesion GPCR Workshop November 5 - 7, 2024 | 16th Annual PEGS Europe   July 12 - 17, 2026 | 20th World Congress of Basic and Clinical Pharmacology GPCR Jobs NEW Postdoc in GPCR mechanosensing   Postdoctoral Position Postdoctoral research position Senior or Lead Researcher   Senior Scientist, Cryo-Electron Microscopy   Postdoctoral Research Associate Join Dr. GPCR Ecosystem

Full Agenda Coming Soon! Are you interested in boosting your brand? ’ Award: Pioneering GPCR-Driven Immunotherapies in Cancer Treatment Structure Therapeutics Appoints Angus

September 2022 Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following Angiotensin 1-7 (Ang-1-7), an endogenous peptide, acts at the G protein coupled MAS1 receptors (MASR) Few studies have identified whether Ang-(1-7) decreases cognitive impairment following closed TBI. This study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model

October 2022 Pharmacological targeting of cGAS/STING-YAP axis suppresses pathological angiogenesis and ameliorates organ fibrosis "Organ fibrosis is accompanied by pathological angiogenesis. Discovering new ways to ameliorate pathological angiogenesis may bypass organ fibrosis. This study unveiled a new antifibrotic cGAS/STING signaling pathway that suppresses pathological angiogenesis support that activation of cGAS/STING signaling mitigates organ fibrosis and suppresses pathological angiogenesis

Comparative evaluation of biased agonists Sarcosine1 , d-Alanine8 -Angiotensin (Ang) II (SD Ang II) and Sarcosine1 , Isoleucine8 -Ang II (SI Ang II) and their radioiodinated congeners binding to rat liver GPCRs in Oncology and Immunology LP2, a cyclic angiotensin-(1-7) analog extended with an N-terminal D-lysine

perspectives on the mechanism of signal activation, ligand selectivity and allosteric modulation in angiotensin advances have guided our knowledge of physiological and fatal pathological mechanisms of the hormone angiotensin II (AngII) and its antagonists. Recently, X-ray structures of both AngII receptors (AT1 and AT2 receptors) bound to peptide and non-peptide knowledge can be transformative in understanding the mechanisms underlying the physiology of AngII."

September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling

in GPCR Research Probing PAC1 receptor activation across species with an engineered sensor A Multi-Angle

progression and therapy Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin

Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular

homotrimeric GPCR architecture of the human cytomegalovirus revealed by cryo-EM Antibodies expand the scope of angiotensin

for a Key GPCR Target GPCRs in Cardiology, Endocrinology, and Taste Orphan GPCR GPRC5C Facilitates Angiotensin

Stay tuned for more information coming soon. Interested in showcasing your research? More details are coming soon—stay tuned! Dr.  protein-coupled receptor, forms oligomers GPCR Activation and Signaling Unraveling the crosstalk between renin-angiotensin

Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular

as agonist's efficacy GPCR Binders, Drugs, and more Nanobody-Mediated Dualsteric Engagement of the Angiotensin

CXCL10 attenuates glycosaminoglycan binding, CXCR3A signaling and lymphocyte chemotaxis, while retaining angiostatic

binding proteins of G-protein-coupled receptors Reviews, GPCRs, and more RGS proteins and cardiovascular Angiotensin

GPCRs in Cardiology, Endocrinology, and Taste Ageing influences detrusor contractions to prostaglandin, angiotensin

., Angelini, A., Waghray, D., Dror, R. O., Ploegh, H. L., & Garcia, K. C. (2015).

Function, Physiology, and Pharmacological Perspectives COVID-19, G protein-coupled receptor, and renin-angiotensin

Hébert and their colleagues research on 'G Protein-Biased Agonists for Intracellular Angiotensin Receptors GPCR Activation and Signaling G Protein-Biased Agonists for Intracellular Angiotensin Receptors Promote

Al 2017) and its activation promotes migration and angiogenesis (Kim S. et. al 2015).

Biased agonists differentially modulate the receptor conformation ensembles in Angiotensin II type 1

neurons, selectively reduces CaV 3.2 and CaV 3.3 currents GPCR Binders, Drugs, and more LP2, a cyclic angiotensin

These receptors are expressed widely and involved in various functions including development, angiogenesis

This is why sympatholytic treatments (such as β-blockers) and renin-angiotensin system inhibitors or mineralocorticoid receptor antagonists, which block the effects of angiotensin II (AngII) and aldosterone tightly regulated by adrenal G protein-coupled receptors (GPCRs), such as adrenergic receptors and AngII HF, by focusing on the 2 best studied adrenal GPCR types in that context, adrenergic receptors and AngII

Dysfunction of B2R is also closely related to cancers and hereditary angioedema (HAE).

several intracellular signaling pathways, regulating cell proliferation, survival, chemotaxis, migration, angiogenesis